Heparin induced thrombocytopaenia secondary to intraperitoneal heparin exposure.
Kaplan
Gilaad G
GG
Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Manns
Braden
B
McLaughlin
Kevin
K
D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007274:Injections, Intraperitoneal; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D010538:Peritonitis / Q000188:drug therapy / Q000209:etiology; D010976:Platelet Count; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced*
D005343:Fibrinolytic Agents; D006493:Heparin